SCHEMBL18366136

SCHEMBL18366136

CCC1(C)OCc2cnc(C(=O)OC)cc21

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 2/20 0.63
ALDH1A1 P00352 5/20 0.37
HPGD P15428 5/20 0.37
KDM4E B2RXH2 4/20 0.37
NPC1 O15118 3/20 0.37
RAB9A P51151 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
GAA P10253 1/20 0.37
MAPK1 P28482 1/20 0.36
LCK P06239 1/20 0.36
GABRP O00591 3/20 0.35
GABRD O14764 3/20 0.35
GABRA1 P14867 3/20 0.35
GABRB1 P18505 3/20 0.35
GABRG2 P18507 3/20 0.35
GABRB3 P28472 3/20 0.35
GABRA5 P31644 3/20 0.35
GABRA3 P34903 3/20 0.35
GABRA2 P47869 3/20 0.35
GABRB2 P47870 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30015041 1.00 RIPK1 (0.63) RIPK1ALDH1A1HPGDKDM4ENPC1
SCHEMBL30092704 0.89 RIPK1 (0.50) RIPK1ALDH1A1HPGDKDM4ENPC1
SCHEMBL18366444 0.89 RIPK1 (0.50) RIPK1ALDH1A1HPGDKDM4ENPC1
SCHEMBL19659459 0.87 RIPK1 (0.68) RIPK1ALDH1A1HPGDKDM4ENPC1
SCHEMBL30092636 0.85 RIPK1 (0.50) RIPK1ALDH1A1HPGDKDM4EMAPK1
SCHEMBL30092638 0.85 RIPK1 (0.50) RIPK1ALDH1A1HPGDKDM4EMAPK1
SCHEMBL18372660 0.85 RIPK1 (0.50) RIPK1ALDH1A1HPGDKDM4EMAPK1
SCHEMBL19641479 0.85 RIPK1 (0.67) RIPK1ALDH1A1HPGDKDM4ENPC1
SCHEMBL18365949 0.85 RIPK1 (0.67) RIPK1ALDH1A1HPGDKDM4ENPC1
SCHEMBL30092753 0.85 RIPK1 (0.67) RIPK1ALDH1A1HPGDKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3548484-B1 BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF HOFFMANN LA ROCHE (CH) 2025-04-30 EP disclosed
US-11607396-B2 Bicyclic amide compounds and methods of use thereof GENENTECH, INC. (US) 2023-03-21 US disclosed
US-20220339129-A1 BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2022-10-27 US disclosed
CN-110023313-B Bicyclic amide compounds and methods of use thereof 豪夫迈·罗氏有限公司 2022-10-25 CN disclosed
US-11071721-B2 Bicyclic amide compounds and methods of use thereof GENENTECH, INC. (US) 2021-07-27 US disclosed
US-11071721-B2 Bicyclic amide compounds and methods of use thereof GENENTECH, INC. (US) 2021-07-27 US disclosed
US-10988459-B2 Bicyclic lactams and methods of use thereof GENENTECH, INC. (US) 2021-04-27 US disclosed
US-10933036-B2 2021-03-02 US disclosed
US-10933036-B2 2021-03-02 US disclosed
EP-3760625-A1 BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES F. Hoffmann-La Roche AG (CH) 2021-01-06 EP disclosed
EP-3548484-A1 BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF F. Hoffmann-La Roche AG (CH) 2019-10-09 EP disclosed
US-20180153831-A1 BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2018-06-07 US disclosed
WO-2018100070-A1 BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2018-06-07 WO disclosed
WO-2018100070-A1 BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2018-06-07 WO disclosed
US-20180153831-A1 BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2018-06-07 US disclosed
US-20180153831-A1 BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2018-06-07 US disclosed
WO-2017004500-A9 BICYCLIC LACTAMS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-11-30 WO disclosed
US-20170008877-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-01-12 US disclosed
US-20170008877-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-01-12 US disclosed
WO-2017004500-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11607396-B2 Bicyclic amide compounds and methods of use thereof CYP4B1, CYP1B1, AADAC RIPK1 4061/4885ALDH1A1 786/4885HPGD 1540/4885
US-10988459-B2 Bicyclic lactams and methods of use thereof LSS, LPXN, CYP1B1 RIPK1 3064/4885ALDH1A1 1195/4885HPGD 2167/4885
US-20220339129-A1 BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF CYP4B1, CYP1B1, AADAC RIPK1 4061/4885ALDH1A1 786/4885HPGD 1540/4885
US-20180153831-A1 BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF CYP4B1, CYP1B1, AADAC RIPK1 4061/4885ALDH1A1 786/4885HPGD 1540/4885
US-11071721-B2 Bicyclic amide compounds and methods of use thereof CYP4B1, CYP1B1, AADAC RIPK1 4061/4885ALDH1A1 786/4885HPGD 1540/4885
US-10933036-B2 CYP1B1, CYP4B1, CYP11B2 RIPK1 4591/4885ALDH1A1 367/4885HPGD 1590/4885
US-20170008877-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF LSS, LPXN, CYP1B1 RIPK1 3064/4885ALDH1A1 1195/4885HPGD 2167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.